Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;10(4):281–294. doi: 10.1111/j.1527-3458.2004.tb00028.x

The Pharmacology of Chlormethiazole: A Potential Neuroprotective Agent?

M J Wilby 1, P J Hutchinson 1,✉
PMCID: PMC6741715  PMID: 15592579

ABSTRACT

Chlormethiazole is a thiazole derivative with a long history of use as a sedative agent. The mode of action of the drug has been partly worked out and has been established with recognition that its mechanism of action involves potentiation of GABA activity, the major intrinsic inhibitory neurotransmitter. Animal models of stroke ranging from rodents to primates have suggested an optimistic role for chlormethiazole in preventing both anatomical and functional deleterious effects of stroke. Phase III clinical trials, therefore, proceeded but unfortunately with very little success. Recently, the animal models have been revisited in an attempt to identify causes for this discrepancy between the results from pre‐clinical and clinical studies. This review studies the pharmacological roots of chlormethiazole from its origin through to its licensed and novel applications. Emphasis is placed on discussing the animal experiments which led to its grooming as a neuroprotective agent and also on the human trials. The review seeks to explain the discrepancies between animal and human studies, which include short survival times of experimental subjects, speed of drug administration and fundamental differences between species. The primate model of stroke perhaps offers the nearest alternative to phase III trials and has recently been used to compare a number of newer neuroprotective agents with greater efficacy than chlormethiazole. In addition, novel approaches involving human neurochemical analyses in vivo are described which may help bridge the gap between animal models and future phase III trials.

Keywords: Stroke, Neuroprotection, Chlormethiazole

Full Text

The Full Text of this article is available as a PDF (125.9 KB).

REFERENCES

  • 1. Centerholt C, Ekblom M, Odergren T, et al. Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole. Eur J Clin Pharmacol 2003;59:117–122. [DOI] [PubMed] [Google Scholar]
  • 2. Chaulk D, Wells J, Evans S, Jackson D, Corbett D. Long‐term effects of clomethiazole in a model of global ischemia. Exp Neurol 2003;182(2):476–482. [DOI] [PubMed] [Google Scholar]
  • 3. Colbourne F, Corbett D. Delayed postischemic hypothermia: A six month survival study using behavioural and histological assessments of neuroprotection. J Neurosci 1995;15(11):7250–7260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Cross AJ, Jones JA, Snares M, Jostell KG, Bredberg U, Green AR. The protective action of chlormethiazole against ischaemia‐induced neurodegeneration in gerbils when infused at doses having little sedative or anticonvulsant activity. Br J Pharmacol 1995;114(8):1625–1630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Cross AJ, Jones JA, Baldwin HA, Green AR. Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil. Br J Pharmacol 1991;104(2):406–411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Eap CB, Schnyder C, Besson J, Savary L, Buclin T. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. Clin Pharmacol Ther 1998;64:52–57. [DOI] [PubMed] [Google Scholar]
  • 7. Empson RM, Gee VJ, Sheardown MJ, Newberry NR. Chlormethiazole inhibits epileptiform activity by potentiating GABAA receptor function. Brain Res 2000;884(1–2):31–34. [DOI] [PubMed] [Google Scholar]
  • 8. Farooque M, Isaksson J, Jackson DM, Olsson Y. Clomethiazole (ZENDRA, CMZ) improves hind limb motor function and reduces neuronal damage after severe spinal cord injury in rat. Acta Neuropathol (Berl) 1997;98:22–30. [DOI] [PubMed] [Google Scholar]
  • 9. Franz M, Dlabal H, Kunz S, Ulferts J, Gruppe H, Gallhofer B. Treatment of alcohol withdrawal: Tiapride and carbamazepine versus clomethiazole. A pilot study. Eur Arch Psychiatry Clin Neurosci 2001;251:185–192. [DOI] [PubMed] [Google Scholar]
  • 10. Gent JP, Wacey TA. The effects of chlormethiazole on single unit activity in rat brain: Interactions with inhibitory and excitatory neurotransmitters. Br J Pharmacol 1983;80(3):439–444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Gray PA, Park GR. Chlormethiazole sedation for critically ill patients in renal failure. Anaesthesia 1989;44:913–915. [DOI] [PubMed] [Google Scholar]
  • 12. Green AR, Murray TK, Misra A, Snape MF, Jones JA, Cross AJ. The metabolism of clomethiazole in gerbils and the neuroprotective and sedative activity of the metabolites. Br J Pharmacol 2000;129:95–100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Green AR, Cross AJ. Attenuation by chlormethiazole of oedema following focal ischaemia in the cerebral cortex of the rat. Neurosci Lett 1994;173(1–2):27–30. [DOI] [PubMed] [Google Scholar]
  • 14. Hales TG, Lambert JJ. Modulation of GABAA and glycine receptors by chlormethiazole. Eur J Pharmacol 1992;210(3):239–246. [DOI] [PubMed] [Google Scholar]
  • 15. Harmon D, Coleman E, Marshall C, Lan W, Shorten G. The effect of clomethiazole on plasma concentrations of interleukin‐6, ‐8, ‐1 beta, tumor necrosis factor‐alpha, and neutrophil adhesion molecule expression during experimental extracorporeal circulation. Anesth Analg 2003;97:13–18. [DOI] [PubMed] [Google Scholar]
  • 16. Harvey PK, Higenbottam TW, Loh L. Chlormethiazole in treatment of status epilepticus. Br Med J 1975;2(5971):603–605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Herran A, Vazquez‐Barquero JL. Treating alcohol dependence. Chlormethiazole is widely used in Europe. Br Med J 1997;315:1466. [PMC free article] [PubMed] [Google Scholar]
  • 18. Hutchinson PJ, O'Connell MT, Coles JP, et al. Investigation of the effect of chlormethiazole on cerebral chemistry in neurosurgical patients: A combined study of microdialysis and a neuroprotective agent. Br J Clin Pharmacol 2002;53:275–283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Kong RS, Butterworth J, Aveling W, et al. Clinical trial of the neuroprotectant clomethiazole in coronary artery bypass graft surgery: A randomized controlled trial. Anesthesiology 2002;97:585–591. [DOI] [PubMed] [Google Scholar]
  • 20. Liang SP, Kanthan R, Shuaib A, Wishart T. Effects of clomethiazole on radial‐arm maze performance following global forebrain ischemia in gerbils. Brain Res 1997;751(2):189–195. [DOI] [PubMed] [Google Scholar]
  • 21. Lyden P, Jacoby M, Schim J, et al. The Clomethiazole Acute Stroke Study in tissue‐type plasminogen activator‐treated stroke (CLASS‐T): Final results. Neurology 2001;57:1199–1205. [DOI] [PubMed] [Google Scholar]
  • 22. Lyden P, Shuaib A, Ng K, et al. Clomethiazole Acute Stroke Study in ischemic stroke (CLASS‐T): Final results. Stroke 2002;33:122–128. [DOI] [PubMed] [Google Scholar]
  • 23. Mahoney FI, Barthel DW. Functional evaluation: The Barthel index. Maryland State Med J 1965;14(Feb):61–65. [PubMed] [Google Scholar]
  • 24. Marshall JW, Cross AJ, Jackson DM, Green AR, Baker HF, Ridley RM. Clomethiazole protects against hemineglect in a primate model of stroke. Brain Res Bull 2000;52:21–29. [DOI] [PubMed] [Google Scholar]
  • 25. Marshall JW, Cross AJ, Ridley RM. Functional benefit from clomethiazole treatment after focal cerebral ischemia in a nonhuman primate species. Exp Neurol 1999;156:121–129. [DOI] [PubMed] [Google Scholar]
  • 26. Marshall JW, Green AR, Ridley RM. Comparison of the neuroprotective effect of clomethiazole, AR‐R15896AR and NXY‐059 in a primate model of stroke using histological and behavioural measures. Brain Res 2003;972:119–126. [DOI] [PubMed] [Google Scholar]
  • 27. Mather LE, Runciman WB, Ilsley AH, Thomson KR, Goldin AR. Direct measurement of chlormethiazole extraction by liver, lung and kidney in man. Br J Clin Pharmacol 1981;12(3):319–325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Modig J. Indications of chlormethiazole as a protective agent in experimental endotoxemia. Eur Surg Res 1988;20:195–204. [DOI] [PubMed] [Google Scholar]
  • 29. Moody EJ, Skolnick P. Chlormethiazole: Neurochemical actions at the γ‐aminobutyric acid receptor complex. Eur J Pharmacol 1989;164(1):153–158. [DOI] [PubMed] [Google Scholar]
  • 30. Nimmerrichter AA, Walter H, Gutierrez‐Lobos KE, Lesch OM. Double‐blind controlled trial of γ‐hydroxy‐butyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol 2002;37:67–73. [DOI] [PubMed] [Google Scholar]
  • 31. Offen CP, Frearson MJ, Wilson K, Burnett D. 4,5‐Dimethylthiazole‐N‐oxide‐S‐oxide: A metabolite of chlormethiazole in man. Xenobiotica 1985;15(6):503–511. [DOI] [PubMed] [Google Scholar]
  • 32. Ogren SO. Chlormethiazole‐mode of action. Acta Psychiatr Scand 1986;329(Suppl):13–27. [PubMed] [Google Scholar]
  • 33. Pathy MS. A double‐blind comparison of chlormethiazole and dichloralphenazone: A sedative/hypnotic in geriatric medicine. Curr Med Res Opin 1974;2:648–656. [DOI] [PubMed] [Google Scholar]
  • 34. Pentikainen PJ, Valtonen VV, Miettinen TA. Deaths in connection with chlormethiazole (heminevrin) therapy. Int J Clin Pharmacol Biopharm 1976;14(3):225–230. [PubMed] [Google Scholar]
  • 35. Ratz AE, Schlienger RG, Linder L, Langewitz W, Haefeli WE. Pharmacokinetics and pharmacodynamics of clomethiazole after oral and rectal administration in healthy subjects. Clin Ther 1999;21:829–840. [DOI] [PubMed] [Google Scholar]
  • 36. Scott DB, Beamish D, Hudson IN, Jostell KG. Prolonged infusion of chlormethiazole in intensive care. Br J Anaesth 1980;52:541–545. [DOI] [PubMed] [Google Scholar]
  • 37. Seow LT, Mather LE, Cousins MJ. Failure of IV atropine to abolish nasal irritation caused by chlormethiazole infusion in elderly patients undergoing spinal anaesthesia. Anaesth Intensive Care 1984;12:127–130. [DOI] [PubMed] [Google Scholar]
  • 38. Seow LT, Mather LE, Cousins MJ. Comparison of the efficacy of chlormethiazole and diazepam as i.v. sedatives for supplementation of extradural anaesthesia. Br J Anaesth 1985;57:747–752. [DOI] [PubMed] [Google Scholar]
  • 39. Seow LT, Mather LE, Roberts JG. An integrated study of pharmacokinetics and pharmacodynamics of chlormethiazole in healthy young volunteers. Eur J Clin Pharmacol 1981;19:263–269. [DOI] [PubMed] [Google Scholar]
  • 40. Shaw G, Bury RW, Mashford ML, Breen KJ, Desmond PV. Cimetidine impairs the elimination of chlormethiazole. Eur J Clin Pharmacol 1981;21:83–85. [DOI] [PubMed] [Google Scholar]
  • 41. Shuaib A, Ijaz S, Kanthan R. Clomethiazole protects the brain in transient forebrain ischemia when used up to 4 h after the insult. Neurosci Lett 1995;197(2):109–112. [DOI] [PubMed] [Google Scholar]
  • 42. Simi A, Ingelman‐Sundberg M, Tindberg N. Neuroprotective agent chlomethiazole attenuates c‐fos, c‐jun, and AP‐1 activation through inhibition of p38 MAP kinase. J Cereb Blood Flow Metab 2000;20(7):1077–1088. [DOI] [PubMed] [Google Scholar]
  • 43. Snape MF, Baldwin HA, Cross AJ, Green AR. The effects of chlormethiazole and nimodipine on cortical infarct area after focal cerebral ischaemia in the rat. Neuroscience 1993;53(3):837–844. [DOI] [PubMed] [Google Scholar]
  • 44. Stanley TV. Chlormethiazole: An effective oral sedative for cranial CT scans in children. Aust Paediatr J 1985;21:191–192. [DOI] [PubMed] [Google Scholar]
  • 45. Sydserff SG, Cross AJ, West KJ, Green AR. The effect of chlormethiazole on neuronal damage in a model of transient focal ischaemia. Br J Pharmacol 1995;114(8):1631–1635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Sydserff SG, Cross AJ, Green AR. The neuroprotective effect of chlormethiazole on ischaemic neuronal damage following permanent middle cerebral artery ischaemia in the rat. Neurodegeneration 1995;4(3):323–328. [DOI] [PubMed] [Google Scholar]
  • 47. Sydserff SG, Green AR, Cross AJ. The effect of oedema and tissue swelling on the measurement of neuroprotection: A study using chlormethiazole and permanent middle cerebral artery occlusion in rats. Neurodegeneration 1996;5:81–85. [DOI] [PubMed] [Google Scholar]
  • 48. Sydserff SG, Cross AJ, Murray TK, Jones JA, Green AR. Clomethiazole is neuroprotective in models of global and focal cerebral ischemia when infused at doses producing clinically relevant plasma concentrations. Brain Res 2000;862:59–62. [DOI] [PubMed] [Google Scholar]
  • 49. Thaminy S, Reymann JM, Heresbach N, Allain H, Lechat P, Bentue‐Ferrer D. Is chlormethiazole neuroprotective in experimental global cerebral ischemia? A microdialysis and behavioral study. Pharmacol Biochem Behav 1997;56(4):737–745. [DOI] [PubMed] [Google Scholar]
  • 50. Wahlgren NG, Diez‐Tejedor E, Teitelbaum J, et al. Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of clomethiazole versus placebo in acute stroke patients. Stroke 2000;31:82–85. [DOI] [PubMed] [Google Scholar]
  • 51. Wahlgren NG, Ranasinha KW, Rosolacci T, et al. Clomethiazole acute stroke study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. Stroke 1999;30:21–28. [DOI] [PubMed] [Google Scholar]
  • 52. Zingmark PH, Ekblom M, Odergren T, et al. Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. Br J Clin Pharmacol 2003;56(2):173–183. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES